Blood Advances · 2023 · 10 citations · 25 references
MedicineOncologyPathologyCellular PathologyNeoplasiaOncogenesHistiocytic DisordersProtein Kinase CascadesReceptor Tyrosine Kinase OncogenesMapk SignalingMitogenic Signal TransductionMitogenic Signaling PathwaysMyeloid NeoplasmsOncogenic Mitogenic SignalingPi3k SignalingPik3ca MutationsTargeted Kinase Inhibition
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm characterized by the accumulation of clonal mononuclear phagocyte system cells expressing CD1a and CD207. In the past decade, molecular profiling of LCH as well as other histiocytic neoplasms demonstrated that these diseases are driven by MAPK activating alterations, with somatic BRAFV600E mutations in >50% of patients with LCH, and clinical inhibition of MAPK signaling has demonstrated remarkable clinical efficacy. At the same time, activating alterations in kinase-encoding genes, such as PIK3CA, ALK, RET, and CSF1R, which can activate mitogenic pathways independent from the MAPK pathway, have been reported in a subset of histiocytic neoplasms with anecdotal evidence of successful targeted treatment of histiocytoses harboring driver alterations in RET, ALK, and CSF1R. However, evidence supporting the biological consequences of expression of PIK3CA mutations in hematopoietic cells has been lacking, and whether targeted inhibition of PI3K is clinically efficacious in histiocytic neoplasms is unknown. Here, we provide evidence that activating mutations in PIK3CA can drive histiocytic neoplasms in vivo using a conditional knockin mouse expressing mutant PIK3CAH1047R in monocyte/dendritic cell progenitors. In parallel, we demonstrate successful treatment of PIK3CA-mutated, multisystemic LCH using alpelisib, an inhibitor of the alpha catalytic subunit of PI3K. Alpelisib demonstrated a tolerable safety profile at a dose of 750 mg per week and clinical and metabolic complete remission in a patient with PIK3CA-mutated LCH. These data demonstrate PIK3CA as a targetable noncanonical driver of LCH and underscore the importance of mutational analysis-based personalized treatment in histiocytic neoplasms.
25
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Fanyin Meng, Roger Henson, Hania Wehbe–Janek et al. · Gastroenterology · 2007 · 2.8K citations · Full text
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +17
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric, Pau Castel, Malachi Griffith et al. · Nature · 2014 · 581 citations · Full text
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Eli L. Diamond, Benjamin H. Durham, Julien Haroche et al. · Cancer Discovery · 2015 · 533 citations · Full text